Status:
UNKNOWN
Evaluation of Efficacy of Lycium Barbarum Polysaccharide in Patients With Major Depressive Disorder
Lead Sponsor:
Guangzhou Psychiatric Hospital
Collaborating Sponsors:
Fifth Affiliated Hospital of Guangzhou Medical University
Conditions:
Major Depressive Disorder
Depression
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Lycium barbarum, a traditional Chinese herbal medicine, is a commonly used herb in the traditional Chinese pharmacopoeia. Its main active ingredient, lycium barbarum polysaccharide (LBP), is reported ...
Eligibility Criteria
Inclusion
- Age: 18-60 years old
- Sex: both men and women
- Compliance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for major depressive disorder
- Hamilton Depression Scale scored more than 18 points.
- No contraindication of taking Lycium barbarum polysaccharide
Exclusion
- Comorbidity with other mental disorders
- Severe somatic diseases
- Current use of traditional Chinese medicine
- Suicide concept, attempt, act and attempted suicide
- Psychiatric symptoms
- Taking hormones and endocrine drugs
- Long-term use of wolfberry in recent three months
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
284 Patients enrolled
Trial Details
Trial ID
NCT04124276
Start Date
November 1 2019
End Date
June 1 2021
Last Update
October 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Brain Hospital (Guangzhou Huiai Hospital)
Guanzhou, Guangdong, China, 510370